| Sep 24 |
Savara appoints Braden Parker as Chief Commercial Officer
|
| Sep 24 |
Savara Appoints Braden Parker as Chief Commercial Officer, Effective Immediately
|
| Sep 23 |
Savara to Host Analyst and Investor Webinar on September 30, 2024
|
| Sep 9 |
Savara: Trial Successful, But I'm Only Half Convinced
|
| Sep 9 |
Why Summit Therapeutics Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
|
| Sep 8 |
Savara Announces New Data from Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Were Presented at the European Respiratory Society (ERS) Congress 2024
|
| Sep 5 |
Exploring Grid Dynamics Holdings And Two High Growth Tech Stocks
|
| Sep 3 |
Savara to Present at the H.C. Wainwright 26th Annual Global Investment Conference
|
| Sep 2 |
Savara, Inc. (SVRA): The Best Multibagger Penny Stock of 2025?
|
| Aug 15 |
Savara to Present New Data from Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the European Respiratory Society (ERS) Congress 2024
|
